CoChat

New Associations between Drug-Induced Adverse Events in Animal Models and Humans Reveal Novel Candidate Safety Targets

Open access
Giblin, Kathryn A., Basili, Danilo, Afzal, Avid M., Rosenbrier-Ribeiro, Lyn, Greene, Nigel, Barrett, Ian, Hughes, Samantha J., Bender, Andreas · 2021 · Chemical Research in Toxicology

The DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.

Abstract

To improve our ability to extrapolate preclinical toxicity to humans, there is a need to understand and quantify the concordance of adverse events (AEs) between animal models and clinical studies. In the present work, we discovered 3011 statistically significant associations between preclinical and clinical AEs caused by drugs reported in the PharmaPendium database of which 2952 were new associations between toxicities encoded by different Medical Dictionary for Regulatory Activities terms across species. To find plausible and testable candidate off-target drug activities for the derived associations, we investigated the genetic overlap between the genes linked to both a preclinical and a clinical AE and the protein targets found to interact with one or more drugs causing both AEs. We discuss three associations from the analysis in more detail for which novel candidate off-target drug activities could be identified, namely, the association of preclinical mutagenicity readouts with clinical teratospermia and ovarian failure, the association of preclinical reflexes abnormal with clinical poor-quality sleep, and the association of preclinical psychomotor hyperactivity with clinical drug withdrawal syndrome . Our analysis successfully identified a total of 77% of known safety targets currently tested in in vitro screening panels plus an additional 431 genes which were proposed for investigation as future safety targets for different clinical toxicities. This work provides new translational toxicity relationships beyond AE term-matching, the results of which can be used for risk profiling of future new chemical entities for clinical studies and for the development of future in vitro safety panels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.chemrestox.0c00311

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 98 references

Research works printed but not linked: 16

  1. (16) Deaton, Aimee M.; Fan, Fan; Zhang, Wei; Nguyen, Phuong A.; Ward, Lucas D.; Nioi, Paul. Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence. Toxicol. Sci. 2019 , 167 , 593-603. -
  2. (20) Nissen, David. Mosby's Drug Consult , 13th ed.; Mosby, 2007. -
  3. (21) Reed Elsevier Properties SA. PharmaPendium https://pharmapendium.com/ (accessed Jun 4, 2018). -
  4. (39) Süleyman, Halis; Demircan, Berna; Karagöz, Yalçin. Anti-Inflammatory and Side Effects of Cyclooxygenase Inhibitors. Pharmacol. Reports 2007 , 59 , 247-258. -
  5. (43) Ahmadian, Maryam; Suh, Jae Myoung; Hah, Nasun; Liddle, Christopher; Atkins, Annette R.; Downes, Michael; Evans, Ronald M. Pparγ Signaling and Metabolism: The Good, the Bad and the Future. Nat. Med. 2013 , 19 , 557-566. -
  6. (55) Whitebread, Steven; Hamon, Jacques; Bojanic, Dejan; Urban, Laszlo. Keynote Review: In Vitro Safety Pharmacology Profiling: An Essential Tool for Successful Drug Development. Drug Discov. Today 2005 , 10 , 1421-1433. - · DOI · Paper page
  7. (56) Santos, Cynthia; Olmedo, Ruben E. Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment. Emerg. Med. Pract. 2017 , 19 , 1-20. -
  8. (63) Haughey, Heather M.; Marshall, Erin; Schacht, Joseph P.; Louis, Ashleigh; Hutchison, Kent E. Marijuana Withdrawal and Craving: Influence of the Cannabinoid Receptor 1 ( CNR1 ) and Fatty Acid Amide Hydrolase ( FAAH ) Genes. Addiction 2008 , 103 , 16781686. -
  9. (72) Komori, Shinji; Kasumi, Hiroyuki; Sakata, Kazuko; Koyama, Koji. The Role of Androgens in Spermatogenesis. Soc. Reprod. Fertil. Suppl. 2007 , 63 , 25-30. -
  10. (78) Brown, Elliot G.; Wood, Louise; Wood, Sue. The Medical Dictionary for Regulatory Activities (MedDRA). In Drug Safety ; John Wiley & Sons, Ltd: Chichester, UK, 1999; Vol. 20, pp 109-117. -
  11. (81) Li, Wentian. Mutual Information Functions Versus Correlation Functions in Binary Sequences. J. Stat. Phys. 2012 , 60 , 249-252. -
  12. (89) Berthold, Michael R.; Cebron, Nicolas; Dill, Fabian; Gabriel, Thomas R.; Kötter, Tobias; Meinl, Thorsten; Ohl, Peter; Thiel, Kilian; Wiswedel, Bernd. KNIME - the Konstanz Information Miner. In ACM SIGKDD Explorations Newsletter ; Preisach C., Burkhardt H., Schmidt-Thieme L., Decker R., Ed.; Springer: Berlin, Heidelberg, 2009; Vol. 11, p 26. -
  13. (90) Krejsa, Cecile M.; Horvath, Dragos; Rogalski, Sherri L.; Penzotti, Julie E.; Mao, Boryeu; Barbosa, Frédérique; Migeon, Jacques C. Predicting ADME Properties and Side Effects: The BioPrint Approach. Curr. Opin. Drug Discov. Devel. 2003 , 6 , 470-480. -
  14. (107) Mungall, Christopher J.; Koehler, Sebastian; Robinson, Peter; Holmes, Ian; Haendel, Melissa. K-BOOM: A Bayesian Approach to Ontology Structure Inference, with Applications in Disease Ontology Construction. bioRxiv 2019 , 048843. -
  15. (108) Mohammed, Osama; Benlamri, Rachid; Fong, Simon. Building a Diseases Symptoms Ontology for Medical Diagnosis: An Integrative Approach. In 1st International Conference on Future Generation Communication Technologies, FGCT 2012 ; IEEE, 2012; pp 104-108. -
  16. (116) Mungall, Christopher J.; McMurry, Julie A.; Köhler, Sebastian; Balhoff, James P.; Borromeo, Charles; Brush, Matthew; Carbon, Seth; Conlin, Tom; Dunn, Nathan; Engelstad, Mark; Foster, Erin; Gourdine, J. P.; Jacobsen, Julius O. B.; Keith, Dan; Laraway, Bryan; Lewis, Suzanna E.; NguyenXuan, Jeremy; Shefchek, Kent; Vasilevsky, Nicole; et al. The Monarch Initiative: An Integrative Data and Analytic Platform Connecting Phenotypes to Genotypes across Species. Nucleic Acids Res. 2017 , 45 , D712-D722. -

Cited by

See all 18

Metadata

Authors
Giblin, K. A., Basili, D., Afzal, A. M., Rosenbrier-Ribeiro, L., Greene, N., Barrett, I., Hughes, S. J., & Bender, A.
Affiliations
  • AstraZeneca (United Kingdom) (GB)
  • University of Cambridge (GB)
  • Safety Platforms, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom
  • AstraZeneca (United States) (US)
Corresponding author
  • Giblin, Kathryn A.
  • Bender, Andreas
Venue
Chemical Research in Toxicology
Published
2020-12-18
Volume
34
Issue
2
Pages
438-451
ISSN
  • 0893-228X (ISSN-L)
  • 1520-5010
OpenAlex
W3117596366
Cited by
18
References
99
Citations by year
2026: 5 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 3
FWCI
1.67
Type
journal article
Language
en
Open access
Locations
  • Chemical Research in Toxicology (publishedVersion)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • AstraZeneca (RG82499)
  • FP7 Ideas: European Research Council (336159)
Topics
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
drug-induced adverse events, animal models, mutagenicity, teratozoospermia, ovarian failure, sleep quality, drug withdrawal syndrome
MeSH terms
Animals, Pharmaceutical Preparations, Humans, Molecular Structure, Databases, Factual, Adverse Drug Reaction Reporting Systems, Models, Animal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.